Product Description
LFA-1 inhibitor
Mechanisms of Action: LFA1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Boehringer Ingelheim
Company Location: Europe
Company Founding Year: 1885
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Psoriasis|Multiple Sclerosis
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02256878 |
NCT02256878 | P1 |
Completed |
Healthy Volunteers |
2006-11-01 |
2019-03-20 |
Treatments |
|
NCT02256813 |
NCT02256813 | P1 |
Completed |
Healthy Volunteers |
2005-12-01 |
2019-03-20 |
Treatments |
|
NCT02256748 |
NCT02256748 | P1 |
Completed |
Healthy Volunteers |
2005-08-01 |
2019-03-20 |
Treatments |
|
NCT02256761 |
NCT02256761 | P1 |
Completed |
Healthy Volunteers |
2005-07-01 |
2019-03-20 |
Treatments |
|
NCT02259894 |
NCT02259894 | P1 |
Completed |
Healthy Volunteers |
2004-06-01 |
2019-03-20 |
||
2007-004328-18 |
2007-004328-18 | P2 |
Completed |
Psoriasis |
2008-06-09 |
2022-03-12 |
Treatments |
|
NCT00333411 |
NCT00333411 | P2 |
Completed |
Psoriasis |
2008-06-01 |
2019-03-21 |
||
2005-005368-10 |
2005-005368-10 | P2 |
Terminated |
Psoriasis |
2007-05-03 |
2022-03-12 |
Treatments |
|
2005-005985-35 |
2005-005985-35 | P2 |
Completed |
Multiple Sclerosis |
2007-02-09 |
2022-03-12 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|